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Abstract
Background: Novel anticoagulations (NOACs) are increasingly prescribed for the prevention of stroke in premenopausal
women with atrial fibrillation. Small studies suggest NOACs are associated with a higher risk of abnormal uterine bleeds
than vitamin K antagonists (VKAs). Because there is no direct empirical evidence on the benefit/risk profile of rivaroxaban
compared to VKAs in this subgroup, we synthesize available indirect evidence, estimate decision uncertainty on the
treatments, and assess whether further research in premenopausal women is warranted.
Methods: A Markov model with annual cycles and a lifetime horizon was developed comparing rivaroxaban (the most
frequently prescribed NOAC in this population) and VKAs. Clinical event rates, associated quality adjusted life years, and
health care costs were obtained from different sources and adjusted for gender, age, and history of stroke. A Monte Carlo
simulation with 10,000 iterations was then performed for a hypothetical cohort of premenopausal women, estimated to
be reflective of the population of premenopausal women with AF in The Netherlands.
Results: In the simulation, rivaroxaban is the better treatment option for the prevention of ischemic strokes
in premenopausal women in 61% of the iterations. Similarly, this is 98% for intracranial hemorrhages, 24%
for major abnormal uterine bleeds, 1% for minor abnormal uterine bleeds, 9% for other major extracranial
hemorrhages, and 23% for other minor extracranial hemorrhages. There is a 78% chance that rivaroxaban
offers the most quality-adjusted life years. The expected value of perfect information in The Netherlands
equals 122 quality-adjusted life years and 22 million Euros.
Conclusions: There is a 22% risk that rivaroxaban offers a worse rather than a better benefit/risk profile
than vitamin K antagonists in premenopausal women. Although rivaroxaban is preferred over VKAs in this
population, further research is warranted, and should preferably take the shape of an internationally
coordinated registry study including other NOACs.
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Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia and is a chronic or recurrent illness that
greatly affects patients’ quality of life. It is estimated that
over 2% of people suffer from AF and its prevalence is
expected to increase, in part due to population ageing in
combination with a deterioration of lifestyle factors such
as overweight, leading to more diabetes, hypertension
and ischemic heart disease at a young age [1–3]. AF
drastically increases the risk of ischemic stroke, and
Vitamin K Antagonists (VKAs) have been prescribed for
decades to prevent such stroke events in patients with
AF. Unfortunately, VKAs are associated with serious
side-effects, of which intracranial hemorrhage is the
most severe, causing extremely high rates of emergency
hospital admissions [4], requiring regular monitoring for
dose titration [5].
Since 2010, four different pharmaceutical agents have
entered the market as an alternative to VKAs: dabiga-
tran, rivaroxaban, apixaban and edoxaban. Their phase
III trials suggest that these novel oral anticoagulants
(NOACs) are at least non-inferior to VKAs in terms of
effectiveness, and are associated with a lower risk of
intracranial hemorrhages [6–10]. Another important
benefit of NOACs is that they are provided in a standard
dose and do not require frequent monitoring. Results
from observational studies suggest that rivaroxaban
(Rvx) is the most prescribed NOAC, at least in Canada
and the UK [11, 12]. A plausible reason for its popularity
is that RVX is taken once daily, where other NOACs
have a twice daily dose regimen [13].
Regardless of the advantages that RVX provides, some
researchers and clinicians still have reservations in clin-
ical practice. A main problem with RVX is that - as for
other NOACs - there is a lack of empirical evidence on
its benefit/risk profile in certain patient subgroups, and
premenopausal women form a marked example, for
whom an important neglected factor is that RVX is asso-
ciated with a higher risk of abnormal uterine bleeds
(AUBs) than VKAs [14, 15]. It is therefore possible that
RVX might be the “wrong” treatment choice for pre-
menopausal women, and that its widespread use in this
subgroup may cause more harm than benefit, especially
considering that heavy and irregular menstrual bleeding
is common in women in their forties and requires spe-
cific attention [16].
As premenopausal women have not been separately
investigated, we aim to assess the impact of RVX pre-
scription in this subgroup by synthesizing and modeling
all relevant indirect empirical evidence that is currently
available. We have done this by simulating clinical event
rates from the phase III trial on RVX, and the different
subgroup analyses performed on this trial (sometimes
adjusted using additional empirical evidence), and the
consequences of these events in a hypothetical cohort of
premenopausal women in a specific model. An adjoining
value-of-information analysis shows whether further re-
search in this subgroup is warranted.
Methods
Model description
A decision-analytic Markov model with annual cycles
and a lifetime horizon was developed in which VKAs
and RVX were compared as treatments for the preven-
tion of stroke in premenopausal women with AF. VKAs
were provided in adjusted doses (target INR between 2.0
and 3.0) and RVX in a dose of 20 mg. The model in-
cluded five different health states – “no history of
stroke”, “previous stroke or TIA”, “previous stroke and
minor disability”, “previous stroke and major disability”,
and “death” – and nine clinical events: ischemic stroke,
TIA, systemic embolism, myocardial infarction, intracra-
nial hemorrhage, major and minor abnormal uterine
bleeds (AUBs), and other major and minor extracranial
hemorrhages. In each cycle, women from the hypothet-
ical cohort remained in their health state or moved from
one health state to another when a TIA, ischemic stroke,
intracranial hemorrhage, or death occurred. See Fig. 1
for an overview of the model.
Population
At baseline, the cohort of women in our analysis was
20 years of age and 0.5% had a history of stroke. This es-
timate was based on consultation of clinical experts.
Menopause was assumed to set in at age 51 years. After
this age, the occurrence of abnormal uterine bleeds is
less common in women, although they do occur. In the
model we conservatively assumed that after 51 years of
age, women were no longer at risk for abnormal uterine
bleeds. Based on the age distribution of premenopausal
women in the Netherlands in 2015 and different studies
on the prevalence of AF in age subgroups, [1, 2, 17, 18]
we estimated that 10,000 premenopausal women had AF
in The Netherlands in 2015, of which 10.5% were aged
20–29 years, 20% were 30–39, 49% were 40–49, and
20.5% were 50–51 years. We assumed that around 40%
of these women were eligible for oral anticoagulation
due to their co-morbidities [2]. See Additional file 1 (in-
cluding Table S1) for more details.
This study focuses on a simulation model of a hypo-
thetical cohort of premenopausal women with AF. Data
on this cohort was based solely on publicly available
data. This study was therefore not submitted to an insti-
tutional ethics committee. Approval from an ethics com-
mittee is required in The Netherlands only when
scientific research subjects persons to at least one inter-
vention or imposes on them a form of behavior, as stated
in the Medical Research Involving Human Subjects Act.
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Probabilities
Clinical event rates were retrieved from different studies
on the phase III trial on RVX [8, 19, 20] as well as a post
approval study on RVX and VKAs for the prevention of
venous thromboembolism in premenopausal women [8,
15]. The study population from the ROCKET-AF trial
differed from the hypothetical cohort of premenopausal
women in terms of gender, age, and history of stroke.
This was important to consider as these variables influ-
ence the risk of different clinical events with VKAs as
well as the relative risks with RVX. Adjustments were
made for different clinical events on the basis of gender,
age and history of stroke using different sources [8, 19–
23]. The clinical event rates and risk adjustments that
were used are listed in Additional file 1: Table S2.
Utility
To assess whether RVX or VKAs form the preferred op-
tion, we needed to compare the benefit/risk profiles of
both treatments. This is difficult because many different
clinical events and health states are important to con-
sider. However, these events and states can be trans-
formed into a single utility measure – quality adjusted
life years (QALYs) – and this measure was used to re-
flect the overall benefit/risk profiles. Quality of life was
considered as a single index utility, on a scale from 0
(representing death) to 1 (representing perfect health).
The decrement in utility caused by clinical events as well
as the utility scores of health events were retrieved from
different sources [24–26]. An overview of (dis)utilities is
provided in Additional file 1: Table S3. QALYs were dis-
counted at an annual rate of 1.5% [27].
Costs
Health care costs were also used as input in the model.
Costs and frequency of treatment/monitoring were col-
lected from the websites of Dutch institutions [28, 29],
and advise from clinical experts. Costs for clinical events
and health states were obtained from health economic
literature [30–33]. Price indices were used to convert
costs to the 2015 price level [34]. Future costs were dis-
counted to their present value by an annual rate of 4%
[27]. An overview of the health care costs associated
with treatment, monitoring, clinical events and health
states can be found in the Additional file 1.
Monte Carlo simulation
We performed a Monte Carlo simulation to obtain
insight into how the uncertainty on the model parame-
ters impact utility and cost-effectiveness. In the simula-
tion, we ran the Markov model 10,000 times for a
hypothetical cohort of 10,000 women aged 20 years,
whereby – for every iteration – parameter values for
clinical event rates, utilities and costs were randomly
Fig. 1 Illustration of the Markov model with health states (circles), clinical events (rectangles), and transition possibilities (arrows). Abbreviations: IS
ischemic stroke, TIA transient ischemic attack, SE systemic embolism, MI myocardial infarction, ICH intracranial hemorrhage, ECH extracranial
hemorrhage (either abnormal uterine bleed or other form of extracranial hemorrhage)
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selected from their uncertainty distributions. The aver-
ages, and the 95% confidence intervals of these averages,
were calculated over the 10,000 iterations, as well as the
average increments of RVX compared to VKAs. We also
calculated in how many iterations RVX performed better
than VKAs with regard to clinical events and QALYs.
Cost-effectiveness of RVX was expressed as the “incre-
mental cost-effectiveness ratio” (ICER) and the “net
monetary benefit” (NMB). The ICER is a standard cost-
effectiveness measure that expresses the healthcare costs
associated with gaining one QALY. It is calculated here
by dividing the incremental costs of RVX by its incre-
mental effects. The NMB is the monetary value assigned
to the total amount of QALYs that is associated with a
treatment, subtracted by the costs of the treatment. The
monetary value that is assigned to QALYs differs per
context; the unofficial value of €50,000 per QALY in the
Netherlands was used in our analysis [27]. The treat-
ment with the highest NMB is considered cost-effective.
Value of information analysis
Through a value of information (VOI) analysis, one can
assess what the impact is of making more informed deci-
sions because uncertainty on what is the best treatment
option is reduced. For this purpose, we estimated the
“expected value of perfect information” (EVPI). The
EVPI is the expected value of eliminating all parameter
uncertainty, here expressed as the maximum in QALYs
that can be gained. The EVPI is estimated by calculating
for each of the 10,000 iterations in the Monte Carlo
simulation the difference between QALYs with the treat-
ment that is chosen under uncertainty and QALYs with
the treatment that would be chosen if “true” parameter
values were known [35].
Not all women who initiate treatment before their
menopause are 20 years old (the baseline age in the base
case analysis). Therefore, the EVPI was calculated for dif-
ferent baseline ages before menopause, namely 20, 30, 40
and 50 years. To estimate the population EVPI, we multi-
plied these age-dependent EVPIs with the estimated num-
ber of women in each age group in The Netherlands.
If the VOI analysis would reveal that further research
is warranted, we further investigated which variables
mainly contribute to the decision uncertainty. A Tor-
nado plot is useful for this purpose, which shows for the
most important model parameters how their uncertainty
influences the results in terms of incremental QALYs.
Results
Monte Carlo simulation
On average, RVX provides better protection against
thromboembolic events and intracranial hemorrhages
than VKAs do, but is associated with a higher risk of all
forms of extracranial hemorrhages (Table 1). However,
for many clinical events there is a large uncertainty on
which treatment provides better protection. For ex-
ample, the risk of ischemic stroke is found to be, on
average, lower with RVX than VKAs – i.e. 0.44 less is-
chemic strokes per 10 patients over their lifetime. How-
ever, according to the 95% uncertainty range, this
incremental effect may be even bigger (down to 3.18 less
ischemic strokes) but RVX may also be harmful, leading
up to 2.22 more ischemic strokes.
The last column shows that, in the 10,000 iterations of
the Monte Carlo simulation, RVX prevents more ische-
mic strokes than VKAs (around 61% of the time). Not-
able from Table 1 is that there is little uncertainty on
which treatment is associated with less intracranial hem-
orrhages (RVX in 98% of the iterations), and less major
non-AUB extracranial hemorrhages and minor AUBs
(VKAs in 91% and 99% of the iterations respectively).
For each iteration in the simulation, the clinical events
associated with each treatment were translated into a
single health-related utility measure, namely QALYs.
Treatment with RVX results, on average, in more
QALYs than treatment with VKAs (30.48 vs. 29.91 per
subject respectively). There is, however, a 22% chance
that VKAs outperform RVX in this respect. This is also
made visible in Fig. 2, which shows all the iterations
from the Monte Carlo simulation, designating for each
iteration the incremental QALYs (x-axis) and incremen-
tal costs (y-axis) with RVX as compared to VKAs.
RVX is associated with higher costs than VKAs in 92%
of the iterations (Table 1). The mean increment of 0.57
QALYs with RVX comes at an average expense of
€16,251. This implies that for every QALY gained with
RVX, an additional expense of €28,506 is required. As-
suming that within Dutch health care policy-makers are
willing to pay €50,000 for each QALY gained, RVX has a
60% probability of being cost-effective.
Value of information analysis
Table 2 shows for each 10-year age group before the age
of 51 the estimated number of women in the
Netherlands in 2015, as well the results from the VOI
analysis. Visible from the table is that the VOI lowers
with rising age. For each woman with a baseline age of
20, perfect information on effectiveness and safety yields
0.0849 QALY and has a net monetary benefit of €12,795
when compared with the current status of uncertainty.
However, these values are 0.0076 and €1710 with a base-
line age of 50. In the total group of premenopausal
women in the Netherlands (2015), perfect information
would improve women’s health with around 122 QALYs
and would yield over 22 million Euros. The net monet-
ary benefit represents the value of gaining QALYs and
preventing healthcare costs because better decisions are
being made.
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The tornado plot in Fig. 3 shows what the impact is of
the uncertainty concerning the relative risks of RVX ver-
sus VKAs on incremental QALYs with RVX as compared
to VKAs with regard to specific parameters. Uncertainty
on the relative risk of ischemic stroke and major abnor-
mal uterine bleeding has the most prominent impact on
incremental QALYs with RVX. For example, under
current uncertainty, the relative risk of ischemic stroke
with RVX vs. VKAs in premenopausal women ranges
from 0.66 to 1.37. If the relative risk would be 1.37,
treatment with RVX will lead to a loss of −0.32 QALYs.
If, on the other side of the spectrum, the relative risk
equals 0.66, treatment with RVX will lead to a gain of
1.69 QALYs. Uncertainty on the relative risk of major
non-AUB extracranial hemorrhages has the least impact
of the parameters shown here; other parameters like the
relative risk of minor hemorrhage, disutilities of clinical
events, and utility scores of health states are not shown
because the impact of their uncertainty is even smaller.
Discussion
We set out to assess the decision uncertainty on whether
RVX or VKAs should be prescribed in premenopausal
women with AF. Although RVX is widely prescribed in
this subgroup [11–13], first results suggested that the
risk of AUB is higher with RVX than with VKAs whereas
it may even be less effective in preventing ischemic
strokes [19]. Using a model-based approach, we esti-
mated that there is a 22% chance that the wrong deci-
sion is being made by prescribing RVX, implicating
worse health outcomes than treatment with VKAs. This
does not imply that there is sufficient reason to withhold
RVX from premenopausal women – after all, RVX
seems to have a 78% probability to have a better benefit/
risk profile than VKAs. However, our study suggests that
more research needs to be done for this subgroup be-
cause of the decision uncertainty.
Further research on the benefit/risk profile of RVX
and VKAs in premenopausal women may add to
decision-making by clinicians and policy-makers. We es-
timate that eliminating uncertainty will yield around 122
QALYs and has a value of over 22 million Euros in the
Netherlands. The risks of ischemic stroke and major
AUB provide the largest contribution to decision uncer-
tainty, and should therefore be of primary concern in
further research. As the number of premenopausal
women with (paroxysmal) AF is relatively low and a
large study population is required to gain enough statis-
tical power to effectively investigate the risk of ischemic
stroke, a large registry study is presumably the best op-
tion for further research, preferably on an international
basis. Another reason to perform a registry study rather
Table 1 Outcomes of the Monte Carlo simulation in which rivaroxaban (RVX) is compared to vitamin K antagonists (VKAs) for the
prevention of stroke in a hypothetical cohort of premenopausal women with atrial fibrillation over their lifetime
Rivaroxaban (RVX) Vitamin K antagonists (VKAs) Increment of RVX vs. VKAs Chance
RVX
performs
better
Mean 95% CIa Mean 95% CIa Mean 95% CIa
Benefit/Risk profile
Clinical events, per 1000 subjects over the lifetime
Ischemic stroke or TIA 567 408 to 759 611 428 to 832 −44 −318 to +222 61%
Systemic embolism 87 36 to 169 102 47 to 182 −15 −110 to +84 63%
Myocardial infarction 319 190 to 496 362 228 to 533 −43 −141 to +49 84%
Intracranial hemorrhage 136 74 to 226 210 146 to 290 −74 −140 to −8 98%
Extracranial hemorrhage (ECH)
Major AUB 928 57 to 1990 429 21 to 894 499 −5.83 to +1690 24%
Major other ECH 1023 685 to 1458 832 639 to 1060 191 −65 to +536 9%
Minor AUB 3872 2194 to 5739 1868 1442 to 2314 2004 227 to +3929 1%
Minor other ECH 3763 2670 to 5137 3401 2716 to 4188 362 −513 to +1436 23%
QALYs, per subject 30.48 26.89 to 33.86 29.91 26.31 to 33.34 0.57 −0.80 to 2.15 78%
Cost-effectiveness (×€1000, per subject)
Healthcare costs 63.7 45.2 to 91.4 47.5 32.5 to 66.7 16.3 −6.1 to 43.1 8%
Costs per QALY gainedb – – – – 28.5 – 60%c
Net monetary benefitc 1460 1276 to 1637 1448 1265 to 1625 12 −75 to 109 60%
aThe lower bound of the range equals the 2.5th percentile, and the upper bound equals the 97.5th percentile
bOtherwise defined as the incremental cost-effectiveness ratio (ICER)
cThe net monetary benefit (NMB) is the monetary value assigned to the total amount of QALYs that is associated with a treatment, subtracted by the costs of the
treatment. We assumed that one QALY was valued with €50,000. The treatment with the highest NMB is considered cost-effective
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than a randomized controlled trial, is that there is cur-
rently no classical equipoise with regard to the right treat-
ment. If other NOACs are prescribed in this population,
these should also be included in the registry study.
The empirical evidence used in our model stems from
various countries and clinical settings, therefore we believe
that the results on the benefit/risk profile per individual are
largely expandable to other countries and settings – al-
though possible discrepancies in time in therapeutic with
VKAs need to be considered. Our simulation model has
several limitations. First, we could not include all currently
available NOACs in our analysis. Although dabigatran,
apixaban and edoxaban are also likely candidates for the
prevention of stroke in premenopausal women with AF, we
decided to restrict our analysis to RVX because this is the
most prescribed NOAC. However, the bleeding risks that
are specific for these women also hold for other NOACs.
Therefore, if other NOACs are prescribed to premeno-
pausal women, the events should also be registered in order
to perform a comprehensive analysis in the future on which
- if any - NOAC is preferred in these specific patients. Sec-
ond, in general, results of modeling studies greatly depend
on the choices made by the researchers, and results might
therefore differ between various studies. For example, we
assumed that treatment decisions were not associated with
Fig. 2 The probabilities that rivaroxaban leads to better or worse health (x-axis) than vitamin K antagonists (VKAs) in terms of Quality Adjusted
Life Years (QALYs) and is more or less costly (y-axis). The figure is the result of the Monte Carlo simulation, in which the Markov model was
iterated 10,000 times, whereby clinical event rates, utility scores and health care costs were randomly selected from their uncertainty distributions
in each iteration
Table 2 The value of reducing the decision uncertainty
surrounding the choice between either rivaroxaban (RVX) or
vitamin K antagonists (VKAs) in premenopausal women with
atrial fibrillation in the Netherlands
Per person Total population
Estimated
chancea
EVPIb Estimated
number
Population EVPIb
QALYs NMB QALYs NMB
Baseline agec
20 yrs 10.5% 0.0849 €12,795 420 35.7 €5,373,900
30 yrs 20% 0.0467 €8311 800 37.4 €6,648,800
40 yrs 49% 0.0219 €4430 1960 42.9 €8,682,800
50 yrs 20.5% 0.0076 €1710 820 6.2 €1,402,200
Total 100% 0.0305 €5527 4000 122.2 €22,107,700
aRepresents the chance that the female patient with atrial fibrillation belongs
to the respective age category
bExpected value of perfect information, which equals the outcomes (in terms
of QALYs or NMB) when making treatment decisions under perfect
information, subtracted with the outcomes when making decisions under
current uncertainty. The EVPI consequently also equals the maximum value of
information that can be gained with further research
cWe assumed that the probability of having suffered a previous stroke
increases with age: 0.5% in women aged 20; 1% in women aged 30; 2% in
women aged 40; and 5% in women aged 50 years
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a decrement in quality of life. In contrast, several previous
cost-effectiveness studies on NOACs did include such dec-
rements [36–38]. We acknowledge that treatment with
VKAs are potentially associated with more inconvenience,
but do not consider this to have an impact on health-related
quality of life. Also, self-measurement of INR may be very
common under younger AF patients, and may be less costly
than visits to thrombotic clinics. Because we did not include
self-measurement in our analysis, the costs associated with
treatment with VKAs may be overestimated, which means
cost-effectiveness of RVX may also be overestimated.
Our study shows that the limited inclusion of premen-
opausal women in the phase III trial on RVX, and the
omission of a subgroup analysis on them, has provoked
decision uncertainty in clinical practice which may be
potential harmful for them. This is related to the recur-
ring fact that women are underrepresented in clinical
trials, often leading to a false extrapolation of general re-
sults [39–41]. Of course, it is important to consider that
specific subgroups may need to be excluded from phase
III trials for ethical reasons, but the choice for patient
exclusion is often not made explicit, raising questions on
whether exclusion was justifiable [42, 43].
We propose a more frequent use of model-based studies
to aid clinicians in decision making for optimal treatment
when clinical study data are missing. Results from such an
analyses may also be helpful for funding agencies or gov-
ernmental bodies in prioritizing research [44, 45], also
with the purpose of preventing wasteful studies [46].
Conclusions
As AF often affects patients for the remainder of their
life, it is important that the justified weighing of benefits
and risks of long-term treatment are being made. We set
out to assess the decision uncertainty surrounding a
promising new treatment for AF in premenopausal
women, a growing subgroup that has been overlooked in
previous trials. Our study shows that although RVX
seems promising, there is still uncertainty on whether
RVX or VKAs should be prescribed in premenopausal
women, mainly because of the uncertainty on the risk of
AUBs and ischemic strokes. Further research on the use
of NOACs in premenopausal women is warranted, and
should preferably take the form of an internationally co-
ordinated registry study. Estimating and reducing uncer-
tainty on treatment decisions will benefit public health,
and estimating the value of additional research may pre-
vent additional wasteful research.
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Fig. 3 Tornado plot: Overview of the impact of the main health outcomes on decision uncertainty. The figure shows the impact of the current
uncertainty on the relative risks (RRs) of rivaroxaban vs. Vitamin K Antagonists (VKAs) in premenopausal women with atrial fibrillation on Quality
Adjusted Life Years (QALYs). For example, the RR of ischemic stroke with rivaroxaban vs. VKAs in premenopausal women currently ranges from
0.66 to 1.37. When the RR is 1.37, treatment with rivaroxaban leads to a loss of −0.32 QALYs. If the RR is 0.66, treatment with rivaroxaban leads to
a gain of 1.69 QALYs
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